Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — Q3 2024 Earnings Presentation
20 slides from Niagen Bioscience's earnings presentation, Oct 31, 2024
Slide 1: ChromaDex Earnings Presentation Third Quarter 2024
ChromaDex Earnings Presentation Third Quarter 2024 Rob Fried Chief Executive Officer Ozan Pamir Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | October 31, 2024
Slide 2: Safe Harbor Statement
This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-
Slide 3: Q3 2024 & Recent Highlights
Q3 2024 & Recent Highlights • Total company and Tru Niagen® net sales of $25.6 million and $18.1 million, up 31%, and 4% YoY, respectively. • Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $6.7 million, up 368% YoY. • Delivered a strong gross margin of 63.5%,
Slide 4: Management Team
Management Team Rob Fried Ozan Pamir Chief Executive Officer Chief Financial Officer E-commerce & entertainment Over a decade of capital industry executive markets and public company experience in the life sciences Savoy Pictures, Columbia industry Pictures, Fried Films, FeeIn, WHN, Healthspan Resea
Slide 5: Financial Highlights
Financial Highlights The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019)
Slide 6: Q3 2024 Net Sales Mix
Q3 2024 Net Sales Mix Q3 2024 Q3 2023 Watson's & Other B2B 13% E-Commerce 65% Watson's & Other B2B 24% E-Commerce 58% Food-grade Niagen® 23% $25.6 MM $19.5 MM Food-grade Niagen® 7% Pharmaceutical-grade Niagen® Analytical Reference 3% Standards & Services 4% Analytical Reference Standards & Services
Slide 7: Q3 2024 Net Sales
Q3 2024 Net Sales Q3 2024 Net Sales Growth Rates ($ in millions) YoY % (vs Q3 2023) E-Commerce 14.8 +16% $18.1 Watson's & Other B2B 3.3 (29)% Food-grade Niagen® 5.8 +304% Pharmaceutical-grade 0.9 N/A Niagen® Analytical Reference 0.8 0% Standards & Services Total +31% Total sales up 31% year-over-yea
Slide 8: Year-to-Date 2024 Net Sales
Year-to-Date 2024 Net Sales Growth Rates YTD 2024 Net Sales ($ in millions) YoY % (vs YTD 2023) E-Commerce 40.7 +7% Watson's & Other B2B 13.4 $54.1 (4)% Food-grade Niagen® 13.0 +66% Pharmaceutical-grade Niagen® 0.9 N/A Analytical Reference 2.3 +4% Standards & Services (60)% Other Ingredients 0.2 Tot
Slide 9: 2022 – 2024 YTD Net Sales Summary
2022 – 2024 YTD Net Sales Summary ($ in millions) 2022 2023 2024 Description Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 E-Commerce 10.9 12.0 11.3 11.1 45.3 12.2 13.0 12.7 13.3 51.2 12.9 13.0 14.8 Watsons 2.6 1.5 2.6 3.3 10.0 3.7 3.0 3.1 3.0 12.8 3.0 3.7 2.0 Other B2B 1.4 1.0 0.7 1.7 4.8 1.7 0.9 1.6 1.3
Slide 10: Q3 2024 vs Q3 2023 Key P&L Metrics
Q3 2024 vs Q3 2023 Key P&L Metrics (in thousands) Q3 2024 Q3 2023 Notes Tru Niagen® and Niagen® ingredient business up 4% and 368%, Net Sales $25,580 $19,495 respectively, driven by higher sales to key food-grade Niagen® partners and the launch of pharmaceutical-grade Niagen®. Up 210bps primarily dr
Slide 11: Adjusted EBITDA Summary
Adjusted EBITDA Summary ChromaDex Corporation and Subsidiaries Reconciliation of Non-GAAP Finanical Measures (In thousands) Three months ended Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Net income (loss), as reported $ (7,740) $ (6,397) $ (985) $ (1,418)
Slide 12: Q3 2024 Operating Income (Loss) vs Q3 2023
Q3 2024 Operating Income (Loss) vs Q3 2023 +$4.4 MM -$1.7 MM (in millions) 4.0 0.2 0.5 3.0 (0.1) (0.1) 3.7 (0.5) 2.0 1.6 (1.0) 1.0 — (1.0) (1.1) (2.0) Q3 2023 Volume Gross Margin Equity Comp Other G+A Severance and Legal Sales & Q3 2024 Operating Loss Improvement (G+A) Restructuring Marketing Operat
Slide 13: Quarterly Balance Sheet Highlights
Quarterly Balance Sheet Highlights (in thousands) 12/31/22 3/31/23 6/30/23 9/30/23 12/31/23 3/31/24 6/30/24 9/30/24 Key Drivers (Q4 2023 vs Q3 2024) Up $5.1 million driven by net income and Cash $20,441 $23,141 $26,406 $26,773 $27,325 $27,565 $27,885 $32,398 proceeds from stock option exercises Down
Slide 14: Quarterly Cash Flow Highlights
Quarterly Cash Flow Highlights (in thousands) FY 2022 3/31/23 6/30/23 9/30/23 12/31/2023 FY 2023 3/31/24 6/30/24 9/30/24 Net Income (Loss) $(16,540) (1) $(1,902) $(2,191) $(959) $114 $(4,938) $(492) $(15) $1,878 Working Capital (5,927) (1) 2,644 3,401 (422) (417) 5,206 (643) (1,837) 1,235 Cash From
Slide 15: 2024 Financial Outlook
2024 Financial Outlook (in thousands) 2022 Actual 2023 Actual 2024 Full Year Outlook Key Drivers Approximately 15% growth YoY • Includes steady recurring revenues from Net Sales $72,050 $83,570 (previously between 10%-15% growth YoY) established partnerships and channels, and upside from the Niagen+
Slide 16: The Science
The Science 16 The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019)
Slide 17: Science Continues to Expand
Science Continues to Expand • Four new human trials on nicotinamide riboside registered since prior update:(1) ▪ University of Oklahoma (August 2024) • Objective: Investigate whether NR supplementation impacts peripheral blood vessel function, cerebral blood flow, and cognitive function in older adu
Slide 18: Scientific Advisory Board
Scientific Advisory Board NOBEL PRIZE WINNERS | CHEMISTRY Charles Brenner, Ph.D. Roger Kornberg, Ph.D. Rudolph Tanzi, Ph.D. Alfred E Mann Family Chairman Kennedy Professor of Foundation Chair, Professor of Structural Neurology Department of Diabetes & Biology Harvard University Cancer Metabolism Sta
Slide 19: Clinical Studies on Oral Niagen® in Multiple Health Areas
Clinical Studies on Oral Niagen® in Multiple Health Areas Note: Highlighted achievements in duration, participation, and dosage only consider peer-reviewed, published studies. Status of clinical studies presented as of October 17, 2024. 19
Slide 20: Contact Info
Contact Info: Ben Shamsian Lytham Partners T: +1(646) 829-9701 Shamsian@LythamPartners.com www.ChromaDex.com Where to buy Tru Niagen® TruNiagen.com Amazon.com The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be